(Q38168795)

English

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

scientific article published on 04 December 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

based on heuristic

inferred from title

author name string

S Carrera

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

A Buque

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

E Azkona

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

U Aresti

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

B Calvo

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

A Sancho

6

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

M Arruti

7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

M Nuño

8

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

I Rubio

9

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

A R de Lobera

10

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

C Lopez

11

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

G L Vivanco

12

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

339-350

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Architecture and membrane interactions of the EGF receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

EGFR-mutated lung cancer: a paradigm of molecular oncology

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

The epidermal growth factor receptor ligands at a glance

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Targeting cancer with small molecule kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Targeting phosphoinositide 3-kinase signalling in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

How genetically engineered mouse tumor models provide insights into human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Oncogene addiction

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

MET pathway as a therapeutic target

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Afatinib (BIBW 2992) development in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1143-9

21 January 2018

Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ALK in lung cancer: past, present, and future

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24307395

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-013-1143-9

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38168795&oldid=2201352484"